Search
Sumario de resultados
TIpos de contenido
Fecha
-
CompanyIBERANIA
-
NewORYZON announces submission of Phase III protocol to FDA to initiate PORTICO-2 trial of v...
PORTICO-2 designed to validate vafidemstat’s efficacy in reducing aggression in BPD patients.
-
NewAseBio presents its proposals to the European Commission for the future Biotech Act
Our contribution addresses the sector’s main challenges with proposals focused on three pillars: agile funding for innovation, simpler and faster regulation, and a more cohesive and globally
-
Press releaseAseBio presents its proposals to the European Commission for the future Biotech Act
We warmly welcome this initiative, convinced that a solid legislative framework is essential to unlocking the full potential of biotechnology for the benefit of the economy, society, and Europe’s
-
NewGENESIS Biomed participated in the valuation of CellsIA, a company acquired by Laboratorio...
GENESIS Biomed provides specialised services in the valuation and search for licensees or acquirers for biomedical projects.
-
NewBeCytes opens new laboratory to accelerate the production of in vitro cellular models
BeCytes Biotechnologies, a company specialized in the research and development of in vitro cellular models, has launched a new laboratory at the Barcelona Science Park (PCB) to expand its production
-
EventBIO-EUROPE SPRING 2026
-
-
NewORYZON to attend the 2025 Phelan-McDermid Syndrome (PMS) Congress in Barcelona on June 26-...
Oryzon’s CSO, Dr. Jordi Xaus, will participate in a Panel entitled “Industry Perspectives Discussion” on June 27.
-
AllyIMCD España Especialidades Químicas, S.A
IMCD es un distribuidor y formulador líder de productos químicos e ingredientes especializados. Aportamos innovación para un mundo más saludable al proporcionar materiales y excipientes con una cadena
-
New#NewAseBioMember| "We also see AseBio as an opportunity to stay aligned with regulatory, s...
Meet our new member Disrupt Therapeutics. We spoke with Patrick Tresserras, CEO y Maria Gallo COO de Disrupt Therapeutics
-
New#NewAseBioMember | "We see AseBio as the go-to platform for fostering synergies within Spa...
Meet our new member Nuage. We spoke with Stuart Hughes, CEO
-
New#NewAseBioMember | “AseBio is a key platform that brings together the main players in the ...
Meet our new member Melius Organics. We spoke with Jordi Mestre, CEO & Cofundador.
-
-
NewR&D investment in the biotech sector grows by 5.2% to 1,282 million euros
In 2023, the activity of biotech companies in Spain generated more than 13,000 million euros of income, which represents 1.1% of the national GDP.
-
Press release
R&D investment in the biotech sector grows by 5.2% to 1,282 million euros
In 2023, the activity of biotech companies in Spain generated more than 13,000 million euros of income, which represents 1.1% of the national GDP. After an exceptional 2023 for the sector in terms of
-
New#NewAseBioMember | “Being a member of AseBio represents a great opportunity to increase ou...
Meet our new member Airway Shield. We spoke with Julio Alonso Babarro, CEO.
-
NewAbilityPharma’s IBRILATAZAR (ABTL0812) doubles overall survival in patients with squamous ...
These results support ibrilatazar as a potential backbone therapy for patients with one of the most common subtypes of lung cancer worldwide, addressing a high- unmet need.
-
New#NewAseBioMember | “AseBio is a key platform for connecting with other biotech players in ...
Meet our new member CIMAB. We spoke with Agustín García-Peiró, CEO and Founder.
-
NewTheriva™ Biologics Announces Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clini...
Safety and clinical outcomes of Phase 1 study of VCN-01 (zabilugene almadenorepvec) in refractory retinoblastoma patients to be presented in a poster session at the American Society of Clinical
-
NewGenetics Becomes an Ally for Healthcare Professionals
Personalized medicine is no longer a promise—it's a reality, with genetics as its key ally. To bring this knowledge into everyday clinical practice, N·GENE was created: a platform that translates
